HCPCS Level II · Drugs administered other than oral method
J3399Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J3399
J3399 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes.
It was added to HCPCS effective 07/01/2020, and its current record took effect 01/01/2024.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Inj onase abepar-xioi treat
- Date added
- 07/01/2020
- Action effective
- 01/01/2024
- BETOS
- O1E
Related J33xx codes
- J3300Injection, triamcinolone acetonide (triesence), preservative free, 1 mg
- J3301Injection, triamcinolone acetonide, not otherwise specified, 10 mg
- J3302Injection, triamcinolone diacetate, per 5 mg
- J3303Injection, triamcinolone hexacetonide, per 5 mg
- J3304Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg
- J3315Injection, triptorelin pamoate, 3.75 mg
- J3316Injection, triptorelin, extended-release, 3.75 mg
- J3350Injection, urea, up to 40 gm
- J3357Ustekinumab, for subcutaneous injection, 1 mg
- J3358Ustekinumab, for intravenous injection, 1 mg
- J3360Injection, diazepam, up to 5 mg
- J3373Injection, vancomycin hydrochloride, 10 mg
Common questions about J3399
Is HCPCS J3399 still valid?
- Yes. J3399 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J3399?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.